Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib are included in international clinical guidelines...

Descripción completa

Detalles Bibliográficos
Autores principales: Randrup Hansen, Caroline, Grimm, Daniela, Bauer, Johann, Wehland, Markus, Magnusson, Nils E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343994/
https://www.ncbi.nlm.nih.gov/pubmed/28230776
http://dx.doi.org/10.3390/ijms18020461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343994/
https://www.ncbi.nlm.nih.gov/pubmed/28230776
http://dx.doi.org/10.3390/ijms18020461

Ejemplares similares